ArticleCell communication and signaling : CCS2026
Fibroblast-derived POSTN promotes colorectal cancer progression under high-fat diet by reprogramming fatty acid metabolism in tumor cell.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Abnormal expression of POSTN is closely related to the development of cancer, especially in colorectal cancer (CRC). However, the effects and mechanisms of POSTN on CRC progression under high-fat diet (HFD) have not been thoroughly studied. The effect of POSTN on HFD-induced CRC was evaluated in vitro and in vivo, and the dynamic changes of different lipid metabolizing enzyme expression were analyzed. Molecular and biological experiments have revealed the underlying mechanisms of POSTN regulating the production of fat accumulation and fatty acid oxidation (FAO) dysregulation. POSTN expression was significantly increased in CRC patients, and was correlated with clinical poor prognosis, mainly derived from myCAF. Deletion of fibroblast-derived POSTN inhibits CRC progression under HFD. Mechanistically, fibroblast-derived POSTN promotes the expression of SREBP1 in tumor cells by regulating the AKT signaling pathway, thereby promoting fatty acid (FA) synthesis. At the same time, fibroblast-derived POSTN inhibits the activity of FAO-related enzyme CPT1A in tumor cells through the ERK signaling pathway, thus inhibiting the FAO process. In addition, we found that CD51 (POSTN receptor) inhibitor Cilengitide effectively inhibits abnormal proliferation of CRC cells, thereby inhibiting tumor development in the HFD environment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.